Netarsudil-associated epithelial keratopathy
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2020/09/01
-
Indian UGC (journal)
-
Refrences4
-
Citations13
-
Meera S. Ramakrishnan ORCID (unauthenticated)
-
Victoria M. Addis
-
Amanda Y. Lehman
-
Prithvi S. Sankar
Cite
Ramakrishnan, Meera S., et al. “Netarsudil-Associated Epithelial Keratopathy”. American Journal of Ophthalmology Case Reports, vol. 19, 2020, p. 100800, https://doi.org/10.1016/j.ajoc.2020.100800.
Ramakrishnan, M. S., Addis, V. M., Lehman, A. Y., & Sankar, P. S. (2020). Netarsudil-associated epithelial keratopathy. American Journal of Ophthalmology Case Reports, 19, 100800. https://doi.org/10.1016/j.ajoc.2020.100800
Ramakrishnan, Meera S., Victoria M. Addis, Amanda Y. Lehman, and Prithvi S. Sankar. “Netarsudil-Associated Epithelial Keratopathy”. American Journal of Ophthalmology Case Reports 19 (2020): 100800. https://doi.org/10.1016/j.ajoc.2020.100800.
1.
Ramakrishnan MS, Addis VM, Lehman AY, Sankar PS. Netarsudil-associated epithelial keratopathy. American Journal of Ophthalmology Case Reports. 2020;19:100800.
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension | Ophthalmology |
| 156 | 2018 |
| Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study | American Journal of Ophthalmology |
| 66 | 2019 |
| Use of topical rho kinase inhibitors in the treatment of Fuchs dystrophy after Descemet stripping only | Cornea |
| 2019 | |
| Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2) | American Journal of Ophthalmology |
| 147 | 2018 |
Refrences Analysis
| Category | Category Repetition |
|---|---|
| Medicine: Ophthalmology | 4 |
| Medicine: Medicine (General) | 4 |
| Medicine | 3 |
The category
Medicine: Ophthalmology 4
is the most frequently represented among the references in this article. It primarily includes studies from American Journal of Ophthalmology and Ophthalmology. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Recent advances in the development of Rho kinase inhibitors (2015–2021) | Medicinal Research Reviews |
| 1 | 2023 |
Netarsudil-associated reticular epithelial corneal edema after phacoemulsification | Journal of Cataract & Refractive Surgery Online Case Reports | 1 | 2023 | |
| Bilateral symmetric honeycomb keratopathy – A rare side effect of netarsudil | Indian Journal of Ophthalmology - Case Reports | 2023 | ||
| Netarsudil-associated reversible “honeycomb” pattern corneal epithelial edema | Journal of Clinical Ophthalmology and Research |
| 2023 | |
| Netarsudil-associated reticular corneal epithelial edema | American Journal of Ophthalmology Case Reports | 10 | 2022 |
Citations Analysis
| Category | Category Repetition |
|---|---|
| Medicine: Ophthalmology | 5 |
| Medicine: Medicine (General) | 4 |
| Medicine: Therapeutics. Pharmacology | 1 |
| Medicine: Public aspects of medicine: Toxicology. Poisons | 1 |
The category
Medicine: Ophthalmology 5
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Netarsudil and was published in 2020. The most recent citation comes from a 2023 study titled Bilateral symmetric honeycomb keratopathy – A rare side effect of netarsudil. This article reached its peak citation in 2022, with 6 citations. It has been cited in 12 different journals, 8% of which are open access. Among related journals, the American Journal of Ophthalmology Case Reports cited this research the most, with 2 citations. The chart below illustrates the annual citation trends for this article.